{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:14:42Z","timestamp":1785860082850,"version":"3.56.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To investigate the efficacy and safety of dexamethasone-lipiodol emulsion in the prevention of post-embolization syndrome after TACE.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>The data of 255 patients who underwent TACE in the interventional department from June 2017 to June 2020 were collected. This is a retrospective assessment of patients who were non-randomly treated with dexamethasone in TACE. The patients were divided into two groups: TACE using lipiodol\u2009+\u2009chemotherapeutic emulsion group (TACE group, N\u2009=\u2009133); TACE using lipiodol\u2009+\u2009dexamethasone\u2009+\u2009chemotherapeutic emulsion group (TACE\u2009+\u2009dexamethasone group, N\u2009=\u2009122). Primary study endpoint: incidence of abdominal pain, fever, nausea and vomiting 0\u201372\u00a0h after TACE in both groups. Secondary study endpoints: incidence of infection after TACE in both groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Incidence of post-embolization syndrome after TACE (TACE group vs TACE\u2009+\u2009dexamethasone group): abdominal pain, 55.6% versus 36.1% (<jats:italic>P<\/jats:italic> value 0.002); fever, 37.6% versus 13.1% (<jats:italic>P<\/jats:italic> value 0.000); nausea, 60.9% versus 41.0% (<jats:italic>P<\/jats:italic> value 0.001); vomiting, 48.1% versus 21.3% (<jats:italic>P<\/jats:italic> value 0.000). Incidence of infection after TACE (TACE group vs TACE\u2009+\u2009dexamethasone group): 1.5% versus 2.5% (<jats:italic>P<\/jats:italic> value 0.583).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The lipiodol\u2009+\u2009dexamethasone emulsion can significantly reduce the incidence rate of post-embolization syndrome after TACE, with exact effect and high safety.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-021-01839-w","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T20:02:36Z","timestamp":1623441756000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy and safety analysis of dexamethasone-lipiodol emulsion in prevention of post-embolization syndrome after TACE: a retrospective analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Haohao","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuansheng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,11]]},"reference":[{"issue":"2","key":"1839_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1053\/j.semdp.2016.12.011","volume":"34","author":"J Hartke","year":"2017","unstructured":"Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellular carcinoma. Semin Diagn Pathol. 2017;34(2):153\u20139. https:\/\/doi.org\/10.1053\/j.semdp.2016.12.011 (Epub 2016 Dec 20 PMID: 28108047).","journal-title":"Semin Diagn Pathol"},{"issue":"6","key":"1839_CR2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1067\/j.cpradiol.2015.04.004","volume":"44","author":"T Clark","year":"2015","unstructured":"Clark T, Maximin S, Meier J, et al. Hepatocellular carcinoma: review of epidemiology, screening, imaging diagnosis, response assessment, and treatment. Curr Probl Diagn Radiol. 2015;44(6):479\u201386. https:\/\/doi.org\/10.1067\/j.cpradiol.2015.04.004 (Epub 2015 Apr 16 PMID: 25979220).","journal-title":"Curr Probl Diagn Radiol"},{"issue":"255","key":"1839_CR3","first-page":"133","volume":"43","author":"A Budny","year":"2017","unstructured":"Budny A, Koz\u0142owski P, Kami\u0144ska M, et al. Epidemiologia i czynniki ryzyka rozwoju raka w\u0105trobowokom\u00f3rkowego [Epidemiology and risk factors of hepatocellular carcinoma]. Pol Merkur Lekarski. 2017;43(255):133\u20139 (Polish. PMID: 28987047).","journal-title":"Pol Merkur Lekarski"},{"issue":"1 suppl","key":"1839_CR4","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/1097-0142(197601)37:1+<532::aid-cncr2820370718>3.0.co;2-k","volume":"37","author":"SR Reuter","year":"1976","unstructured":"Reuter SR. The current status of angiography in the evaluation of cancer patients. Cancer. 1976;37(1 suppl):532\u201341. https:\/\/doi.org\/10.1002\/1097-0142(197601)37:1+%3c532::aid-cncr2820370718%3e3.0.co;2-k (PMID: 942883).","journal-title":"Cancer"},{"issue":"11\u201312","key":"1839_CR5","first-page":"1885","volume":"63","author":"MA Friedman","year":"1979","unstructured":"Friedman MA, Volberding PA, Cassidy MJ, et al. Therapy for hepatocellular cancer with intrahepatic arterial adriamycin and 5-fluorouracil combined with whole-liver irradiation: a Northern California Oncology Group Study. Cancer Treat Rep. 1979;63(11\u201312):1885\u20138 (PMID: 230895).","journal-title":"Cancer Treat Rep"},{"issue":"1","key":"1839_CR6","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/hep.28453","volume":"64","author":"R Lencioni","year":"2016","unstructured":"Lencioni R, de Baere T, Soulen MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology. 2016;64(1):106\u201316. https:\/\/doi.org\/10.1002\/hep.28453 (Epub 2016 Mar 7 PMID: 26765068).","journal-title":"Hepatology"},{"issue":"3","key":"1839_CR7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2214\/AJR.15.14758","volume":"206","author":"LC Casadaban","year":"2016","unstructured":"Casadaban LC, Minocha J, Bui JT, et al. Conventional ethiodized oil transarterial chemoembolization for treatment of hepatocellular carcinoma: contemporary single-center review of clinical outcomes. AJR Am J Roentgenol. 2016;206(3):645\u201354. https:\/\/doi.org\/10.2214\/AJR.15.14758 (PMID: 26901023).","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"1839_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s41747-021-00204-6.PMID:33649930;PMCID:PMC7921261","volume":"5","author":"AA Bessar","year":"2021","unstructured":"Bessar AA, Farag A, Abdel Monem SM, et al. Transarterial chemoembolisation in patients with hepatocellular carcinoma: low-dose doxorubicin reduces post-embolisation syndrome without affecting survival-prospective interventional study. Eur Radiol Exp. 2021;5(1):10. https:\/\/doi.org\/10.1186\/s41747-021-00204-6.PMID:33649930;PMCID:PMC7921261.","journal-title":"Eur Radiol Exp"},{"issue":"3","key":"1839_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/CEJ.0000000000000623","volume":"30","author":"A Gjoreski","year":"2021","unstructured":"Gjoreski A, Jovanoska I, Risteski F, et al. Single-center randomized trial comparing conventional chemoembolization versus doxorubicin-loaded polyethylene glycol microspheres for early- and intermediate-stage hepatocellular carcinoma. Eur J Cancer Prev. 2021;30(3):258\u201366. https:\/\/doi.org\/10.1097\/CEJ.0000000000000623 (PMID: 33038087).","journal-title":"Eur J Cancer Prev"},{"issue":"1","key":"1839_CR10","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1148\/radiol.2018180257","volume":"290","author":"MH Khalaf","year":"2019","unstructured":"Khalaf MH, Sundaram V, AbdelRazek Mohammed MA, et al. A predictive model for postembolization syndrome after transarterial hepatic chemoembolization of hepatocellular carcinoma. Radiology. 2019;290(1):254\u201361. https:\/\/doi.org\/10.1148\/radiol.2018180257 (Epub 2018 Oct 9 PMID: 30299233).","journal-title":"Radiology"},{"issue":"5","key":"1839_CR11","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.ijrobp.2020.04.040","volume":"107","author":"AT Fairchild","year":"2020","unstructured":"Fairchild AT, Tanksley JP, Tenenbaum JD, et al. Interrater reliability in toxicity identification: limitations of current standards. Int J Radiat Oncol Biol Phys. 2020;107(5):996\u20131000. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.04.040 (Epub 2020 May 3 PMID: 32371073).","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1839_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1055\/s-0031-1280666.PMID:22654264;PMCID:PMC3193324","volume":"28","author":"S Dhand","year":"2011","unstructured":"Dhand S, Gupta R. Hepatic transcatheter arterial chemoembolization complicated by postembolization syndrome. Semin Interv Radiol. 2011;28(2):207\u201311. https:\/\/doi.org\/10.1055\/s-0031-1280666.PMID:22654264;PMCID:PMC3193324.","journal-title":"Semin Interv Radiol"},{"issue":"3","key":"1839_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/s1051-0443(07)61911-3","volume":"12","author":"DA Leung","year":"2001","unstructured":"Leung DA, Goin JE, Sickles C, et al. Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol. 2001;12(3):321\u20136. https:\/\/doi.org\/10.1016\/s1051-0443(07)61911-3 (PMID: 11287509).","journal-title":"J Vasc Interv Radiol"},{"issue":"10","key":"1839_CR14","doi-asserted-by":"publisher","first-page":"5995","DOI":"10.7314\/apjcp.2013.14.10.5995","volume":"14","author":"SY Wang","year":"2013","unstructured":"Wang SY, Zhu WH, Vargulick S, et al. Nausea and vomiting after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis. Asian Pac J Cancer Prev. 2013;14(10):5995\u20136000. https:\/\/doi.org\/10.7314\/apjcp.2013.14.10.5995 (PMID: 24289614).","journal-title":"Asian Pac J Cancer Prev"},{"issue":"4","key":"1839_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.18926\/AMO\/56935","volume":"73","author":"K Kuwaki","year":"2019","unstructured":"Kuwaki K, Nouso K, Miyashita M, et al. The efficacy and safety of steroids for preventing postembolization syndrome after transcatheter arterial chemoembolization of hepatocellular carcinoma. Acta Med Okayama. 2019;73(4):333\u20139. https:\/\/doi.org\/10.18926\/AMO\/56935 (PMID: 31439956).","journal-title":"Acta Med Okayama"},{"issue":"Pt 9","key":"1839_CR16","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1242\/jcs.02886.Erratum.In:JCellSci.2007Jul15;120(Pt14):2467","volume":"119","author":"H Oberleithner","year":"2006","unstructured":"Oberleithner H, Riethm\u00fcller C, Ludwig T, et al. Differential action of steroid hormones on human endothelium. J Cell Sci. 2006;119(Pt 9):1926\u201332. https:\/\/doi.org\/10.1242\/jcs.02886.Erratum.In:JCellSci.2007Jul15;120(Pt14):2467 (PMID: 16636077).","journal-title":"J Cell Sci"},{"key":"1839_CR17","doi-asserted-by":"publisher","first-page":"CD012859","DOI":"10.1002\/14651858.CD012859.pub2","volume":"10","author":"S Weibel","year":"2020","unstructured":"Weibel S, R\u00fccker G, Eberhart LH, et al. Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis. Cochrane Database Syst Rev. 2020;10:CD012859. https:\/\/doi.org\/10.1002\/14651858.CD012859.pub2 (PMID: 33075160).","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"1839_CR18","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.asjsur.2019.11.012","volume":"43","author":"J Liu","year":"2020","unstructured":"Liu J, Li H, Zhang J, et al. Dexamethasone or combined with others for postoperative nausea and vomiting in children: a systematic review. Asian J Surg. 2020;43(9):873\u20139. https:\/\/doi.org\/10.1016\/j.asjsur.2019.11.012 (Epub 2020 Jan 18 PMID: 31964583).","journal-title":"Asian J Surg"},{"issue":"2","key":"1839_CR19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.artd.2019.01.007.PMID:31286046;PMCID:PMC6588720","volume":"5","author":"FP Bustos","year":"2019","unstructured":"Bustos FP, Coobs BR, Moskal JT. A retrospective analysis of the use of intravenous dexamethasone for postoperative nausea and vomiting in total joint replacement. Arthroplast Today. 2019;5(2):211\u20135. https:\/\/doi.org\/10.1016\/j.artd.2019.01.007.PMID:31286046;PMCID:PMC6588720.","journal-title":"Arthroplast Today"},{"issue":"3","key":"1839_CR20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/MPG.0000000000002398","volume":"69","author":"H Moheimani","year":"2019","unstructured":"Moheimani H, Yaseri M. Dexamethasone reduces postoperative nausea in pediatric upper endoscopy with deep sedation: a randomized controlled trial. J Pediatr Gastroenterol Nutr. 2019;69(3):281\u20136. https:\/\/doi.org\/10.1097\/MPG.0000000000002398 (PMID: 31124887).","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1839_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-021-04257-7","author":"MA Mahrous","year":"2021","unstructured":"Mahrous MA, El-Azab GA, Tawfik HA. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy. Cancer Chemother Pharmacol. 2021. https:\/\/doi.org\/10.1007\/s00280-021-04257-7 (PMID: 33835230).","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"1839_CR22","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s12185-016-2152-6","volume":"105","author":"A Isoda","year":"2017","unstructured":"Isoda A, Saito R, Komatsu F, et al. Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: a phase II study. Int J Hematol. 2017;105(4):478\u201384. https:\/\/doi.org\/10.1007\/s12185-016-2152-6 (Epub 2016 Nov 21 PMID: 27873176).","journal-title":"Int J Hematol"},{"issue":"12","key":"1839_CR23","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1007\/s00520-012-1469-9","volume":"20","author":"V Lorusso","year":"2012","unstructured":"Lorusso V, Giampaglia M, Petrucelli L, et al. Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy. Support Care Cancer. 2012;20(12):3241\u20136. https:\/\/doi.org\/10.1007\/s00520-012-1469-9 (Epub 2012 Apr 26. PMID: 22534864; PMCID: PMC3480578).","journal-title":"Support Care Cancer"},{"issue":"2","key":"1839_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.suponc.2011.06.007","volume":"10","author":"L Celio","year":"2012","unstructured":"Celio L, Denaro A, Agustoni F, et al. Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial. J Support Oncol. 2012;10(2):65\u201371. https:\/\/doi.org\/10.1016\/j.suponc.2011.06.007 (Epub 2011 Sep 23 PMID: 22005217).","journal-title":"J Support Oncol"},{"key":"1839_CR25","doi-asserted-by":"publisher","DOI":"10.4097\/kja.20640","author":"BG Kim","year":"2021","unstructured":"Kim BG, Lee W, Song JH, et al. Effect of intravenous dexamethasone on the duration of postoperative analgesia for popliteal sciatic nerve block: a randomized, double-blind, placebo-controlled study. Korean J Anesthesiol. 2021. https:\/\/doi.org\/10.4097\/kja.20640 (PMID: 33784802).","journal-title":"Korean J Anesthesiol"},{"key":"1839_CR26","doi-asserted-by":"publisher","DOI":"10.1177\/01455613211000832","author":"ME Kubala","year":"2021","unstructured":"Kubala ME, Turner M, Gardner JR, et al. Impact of oral steroids on tonsillectomy postoperative complications and pain. Ear Nose Throat J. 2021. https:\/\/doi.org\/10.1177\/01455613211000832 (PMID: 33734886).","journal-title":"Ear Nose Throat J"},{"key":"1839_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab065","author":"T Zhang","year":"2021","unstructured":"Zhang T, Xu Y, Yao Y, et al. Randomized controlled trial: perioperative dexamethasone reduces excessive postoperative inflammatory response and ileus after surgery for inflammatory bowel disease. Inflamm Bowel Dis. 2021. https:\/\/doi.org\/10.1093\/ibd\/izab065 (PMID: 33749741).","journal-title":"Inflamm Bowel Dis"},{"key":"1839_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jse.2020.12.005","author":"EA Klag","year":"2021","unstructured":"Klag EA, Kuhlmann NA, Tramer JS, et al. Dexamethasone decreases postoperative opioid and antiemetic use in shoulder arthroplasty patients: a prospective, randomized controlled trial. J Shoulder Elbow Surg. 2021. https:\/\/doi.org\/10.1016\/j.jse.2020.12.005 (PMID: 33486058).","journal-title":"J Shoulder Elbow Surg"},{"key":"1839_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-020-06245-8","author":"L Cheng","year":"2020","unstructured":"Cheng L, Le Y, Yang H, et al. The effect of dexamethasone on pain control after thyroid surgery: a meta-analysis of randomized controlled trials. Eur Arch Otorhinolaryngol. 2020. https:\/\/doi.org\/10.1007\/s00405-020-06245-8 (PMID: 32804272).","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"30","key":"1839_CR30","doi-asserted-by":"publisher","first-page":"e21417","DOI":"10.1097\/MD.0000000000021417.PMID:32791759;PMCID:PMC7387045","volume":"99","author":"L Xu","year":"2020","unstructured":"Xu L, Xie X, Gu X. Dexamethasone for preventing postoperative nausea and vomiting after mastectomy. Medicine (Baltimore). 2020;99(30):e21417. https:\/\/doi.org\/10.1097\/MD.0000000000021417.PMID:32791759;PMCID:PMC7387045.","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"1839_CR31","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1007\/s00520-019-05178-1","volume":"28","author":"T Sakamoto","year":"2020","unstructured":"Sakamoto T, Saito Y, Kobayashi M, et al. Effect of palonosetron and dexamethasone administration on the prevention of gastrointestinal symptoms in hepatic arterial chemoembolization with epirubicin. Support Care Cancer. 2020;28(7):3251\u20137. https:\/\/doi.org\/10.1007\/s00520-019-05178-1 (Epub 2019 Nov 16 PMID: 31732854).","journal-title":"Support Care Cancer"},{"issue":"3","key":"1839_CR32","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jvir.2012.11.019","volume":"24","author":"MJ Kogut","year":"2013","unstructured":"Kogut MJ, Chewning RH, Harris WP, et al. Postembolization syndrome after hepatic transarterial chemoembolization: effect of prophylactic steroids on postprocedure medication requirements. J Vasc Interv Radiol. 2013;24(3):326\u201331. https:\/\/doi.org\/10.1016\/j.jvir.2012.11.019 (Epub 2013 Feb 4 PMID: 23380736).","journal-title":"J Vasc Interv Radiol"},{"issue":"28","key":"1839_CR33","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2017;35(28):3240\u201361. https:\/\/doi.org\/10.1200\/JCO.2017.74.4789 (Epub 2017 Jul 31 PMID: 28759346).","journal-title":"J Clin Oncol"},{"issue":"2","key":"1839_CR34","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/hep.29403","volume":"67","author":"S Ogasawara","year":"2018","unstructured":"Ogasawara S, Chiba T, Ooka Y, et al. A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization. Hepatology. 2018;67(2):575\u201385. https:\/\/doi.org\/10.1002\/hep.29403 (Epub 2017 Dec 23 PMID: 28746788).","journal-title":"Hepatology"},{"issue":"5","key":"1839_CR35","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1097\/NCC.0000000000000302","volume":"39","author":"H Blackburn","year":"2016","unstructured":"Blackburn H, West S. Management of postembolization syndrome following hepatic transarterial chemoembolization for primary or metastatic liver cancer. Cancer Nurs. 2016;39(5):E1\u201318. https:\/\/doi.org\/10.1097\/NCC.0000000000000302 (PMID: 26484962).","journal-title":"Cancer Nurs"},{"issue":"47","key":"1839_CR36","doi-asserted-by":"publisher","first-page":"e23191","DOI":"10.1097\/MD.0000000000023191.PMID:33217828;PMCID:PMC7676579","volume":"99","author":"L Chang","year":"2020","unstructured":"Chang L, Wang W, Jiang N, et al. Dexamethasone prevents TACE-induced adverse events: a meta-analysis. Medicine (Baltimore). 2020;99(47):e23191. https:\/\/doi.org\/10.1097\/MD.0000000000023191.PMID:33217828;PMCID:PMC7676579.","journal-title":"Medicine (Baltimore)"},{"key":"1839_CR37","unstructured":"Young M, John S. Hepatic Chemoembolization. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan\u2013. PMID: 29939599."}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01839-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-021-01839-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01839-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T20:03:21Z","timestamp":1623441801000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-021-01839-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,11]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1839"],"URL":"https:\/\/doi.org\/10.1186\/s12876-021-01839-w","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,11]]},"assertion":[{"value":"22 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The medical ethics committee of our college (Wuhan Union Hospital, Tongji Medical College, Huazhong University of science and technology, Wuhan, Hubei Province) approved the retrospective study. As the study was retrospective, it did not affect the diagnosis and treatment of patients. The medical ethics committee of our college gave up the written informed consent. Although the ethics committee gave up the written consent, for the safety and rationality of the research, all participants signed informed consent for the study. Of course, all the patients signed the informed consent before the operation. During follow-up, we informed patients about the study and they agreed to use their data. We confirm that all methods were performed in accordance with the relevant guidelines and Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants\u2019 information, images and inspection results are agreed to be published and have obtained written consent. The details, images will be freely available on the internet and may be seen by the general public. The consent form is available if requested. These patients have not been reported in any other submission by anyone.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and company that could be construed as influencing the position presented in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"256"}}